FROG/TOAD conditionally silenced vectors for hypoxia gene therapy

Patent metadata

Field	Value
Publication number	US-9394526-B2
Application number	US-201013504438-A
Country	US
Kind code	B2
Filing date	Nov 1, 2010
Priority date	Oct 30, 2009
Publication date	Jul 19, 2016
Grant date	Jul 19, 2016

Abstract

Methods and compositions for the treatment of hypoxia associated disorders by directional angiogenesis/arteriogenesis. Conditionally silenced vectors expressing a therapeutic molecule under hypoxic conditions avoid chaotic vascularization and allow for the orderly growth of new vessels into damaged tissue.

First claim

What is claimed is:

1. A method of treating a patient having a disease or disorder associated with hypoxia or ischemia, comprising directly administering to the patient a composition comprising a conditionally silenced vector comprising: at least one FROG element, at least one TOAD element, at least one hypoxia response element (HRE), a gene encoding at least one growth factor, and a promoter upstream of the gene that is in operable linkage with the gene, the at least one FROG element, the at least one TOAD element, and the at least one HRE, in a therapeutically effective controlled amount for inhibiting necrosis and increasing blood flow in ischemic or hypoxic tissue or organ, wherein the growth factor is not expressed in aerobic tissue but is expressed in the ischemic or hypoxic tissue, wherein the at least one FROG element consists of a nucleotide sequence selected from the group consisting of: SEQ ID NOS: 3 and 4, and the at least one TOAD element consists of a nucleotide sequence selected from the group consisting of: SEQ ID NOS: 1 and 2.

2. A method of treating a patient having a disease or disorder associated with hypoxia or ischemia, comprising directly administering to the patient a composition comprising a conditionally silenced vector comprising: at least one FROG element, at least one TOAD element, at least one hypoxia response element (HRE), a gene encoding at least one growth factor, and a promoter upstream of the gene that is in operable linkage with the gene, the at least one FROG element, the at least one TOAD element, and the at least one HRE, in a therapeutically effective controlled amount for inhibiting necrosis and increasing blood flow in ischemic or hypoxic tissue or organ, wherein the growth factor is not expressed in aerobic tissue but is expressed in the ischemic or hypoxic tissue, wherein the at least one FROG element and the at least one TOAD element consist of a nucleotide sequence selected from the group consisting of: SEQ ID NOS: 5 and 6.

3. The method of claim 1 , wherein the vector further comprises at least one neuronal responsive silencer element (NRSE).

4. The method of claim 1 , wherein the at least one growth factor is selected from the group consisting of: endothelial growth factor, fibroblast growth factor (FGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), transforming growth factor (TGF), hepatocyte growth factor, proliferin, angiotropin, angiopoietin, vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF- beta), insulin like growth factor-1 (IGF-1), nerve growth factor (NGF), stromal derived factor (SDF), stem cell factor (SCF), and erythropoietin (EPO).

5. The method of claim 1 , wherein the tissue or organ is cardiac tissue or limb tissue.

6. The method of claim 1 , wherein the composition is administered intramuscularly.

7. The method of claim 5 , wherein the tissue or organ is limb tissue and the composition is administered intramuscularly.

8. The method of claim 1 , wherein the growth factor is not expressed in normoxic brain cells and normoxic stem cells.

9. The method of claim 1 , wherein the conditionally silenced vector comprises a combined cassette of HREs and TOAD and FROG elements.

Assignees

• Webster Keith A
• Univ Miami

Inventors

• Webster Keith A

Classifications

• C12N15/85

  for animal cells · CPC title

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• C07K14/515

  Angiogenesic factors; Angiogenin · CPC title